See more : Cocrystal Pharma, Inc. (COCP) Income Statement Analysis – Financial Results
Complete financial analysis of Belite Bio, Inc (BLTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Belite Bio, Inc, a leading company in the Biotechnology industry within the Healthcare sector.
- Alpha Healthcare Acquisition Corp. (AHAC) Income Statement Analysis – Financial Results
- Netweb Technologies India Limited (NETWEB.BO) Income Statement Analysis – Financial Results
- Zodiac-JRD-MKJ Limited (ZODJRDMKJ.NS) Income Statement Analysis – Financial Results
- Veritone, Inc. (VERI) Income Statement Analysis – Financial Results
- Snap-on Incorporated (SNA) Income Statement Analysis – Financial Results
Belite Bio, Inc (BLTE)
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 399.00K | 198.00K | 30.00K | 17.00K |
| Gross Profit | -399.00K | -198.00K | -30.00K | -17.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.84M | 8.87M | 7.42M | 3.69M |
| General & Administrative | 6.82M | 3.95M | 2.38M | 2.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.82M | 3.95M | 2.38M | 2.06M |
| Other Expenses | 0.00 | 166.00K | 126.00K | 0.00 |
| Operating Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Cost & Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Interest Income | 74.00K | 23.00K | 5.00K | 12.00K |
| Interest Expense | 25.00K | 16.00K | 0.00 | 21.00K |
| Depreciation & Amortization | 139.00K | 198.00K | 30.00K | 17.00K |
| EBITDA | -31.53M | -12.43M | -9.64M | -5.71M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.67M | -12.82M | -9.80M | -5.74M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.00K | 173.00K | 131.00K | -9.00K |
| Income Before Tax | -31.62M | -12.65M | -9.67M | -5.75M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 9.00K | -173.00K | 126.00K | 1.00K |
| Net Income | -31.63M | -12.48M | -9.79M | -5.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.19 | -0.62 | -0.41 | -0.24 |
| EPS Diluted | -1.19 | -0.62 | -0.41 | -0.24 |
| Weighted Avg Shares Out | 26.59M | 19.98M | 24.10M | 24.10M |
| Weighted Avg Shares Out (Dil) | 26.59M | 19.98M | 24.10M | 24.10M |
Why Shares of Belite Bio Soared This Week
Belite Bio: Undercovered Eye Disease Company With Early Data
Top 5 Health Care Stocks That Are Set To Fly In Q2 - ClearPoint Neuro (NASDAQ:CLPT), Belite Bio (NASDAQ:BLTE)
Why Shares of Belite Bio Are Slumping Wednesday
Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
Belite Bio, Inc (BLTE) Q4 2022 Earnings Call Transcript
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
3 Breakout Growth Stocks to Buy for the Long Haul
These Are the 10 Best-Performing IPOs in 2022 Through October
Source: https://incomestatements.info
Category: Stock Reports